1. FITTER International Congress. October 23–25, 2015. Rome, Italy. BD website. Available from:. https://www.bd.com/resource.aspx?IDX=33000. (accessed 2016 Jun 8).
2. Hong SH, Kim MJ, Noh SG, Suh DW, Youn SJ, Lee KW, Lee HC, Chung YS, Chung HR, Kwon HS, Cha BY, Son HY, Yoon KH. A study on resistance in type 2 diabetic patient against commencement of insulin treatment. Korean Diabetes J. 2008; 32:269–79.
Article
3. Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, Hirsch L, Smith MJ, Wellhoener R, Bode BW, Hirsch IB, Kalra S, Ji L, Strauss KW. New insulin delivery recommendations. Mayo Clin Proceedings. 2016; 91:1231–55.
Article
4. Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012; 14:741–7.
Article
5. Anderson G, Meyer D, Herrman CE, Sheppard C, Murray R, Fox EJ, Mathena J, Conner J, Buck PO. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study. J Neurol. 2010; 257:1917–23.
Article
6. American Association of Diabetes Educators. Insulin pump therapy: best practices in choosing and using infusion devices. Chicago: American Association of Diabetes Educators;2011.
7. Lumber T. Tips for site rotation. When it comes to insulin, where you inject is just as important as how much and when. Diabetes Forecast. 2004; 57:68–70.
8. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013; 39:445–53.
Article
9. Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care. 2008; 31:e65.
Article
10. Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and injecting recommendations for giving injection. Pediatric Diabetes. 2012; 13:525–33.
11. Frid A. Fat thickness and injectable therapy administration, what do we know? Infusystems Int. 2006; 5:17–9.
12. Kaiser P, Maxeiner S, Weise A, Nolden F, Borck A, Forst T, Pfützner A. Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges. J Diabetes Sci Technol. 2010; 4:652–7.
Article
13. Strauss K. Conversation with: Jessie S. 2016 Feb 22. English.